Sleuth maps the top 25 pharma’s pipelines by franchise, matches your best program to where each one is thin, and lists the proof each will ask for, so you can tailor every pitch.
Free to try on your own platform
Each pharma’s programs, deals, and stated priorities, franchise by franchise, with the platforms it already owns or licenses.
What your platform could lead with, matched to each franchise and ranked on cited evidence. Sleuth sets aside any fit that depends on data you don’t have yet.
The pharma that own or license a competing platform, ranked lower with the reason, so you don’t pitch a company that’s building it in house.
For each priority pharma, the case for and against, the objections to expect, the proof to have in hand, and the events to watch before your meeting.
Say what your platform has and hasn’t shown, the decision you face, such as which pharma to meet at a conference coming up, and where you want to focus.
Choose what makes a good partner for you, such as fit with a franchise, deal record, and whether it already owns a competing platform, and how much each one counts.
See the three steps Sleuth will run: map the pipelines, match your programs and rank the pharma, and prepare each outreach. Add a company or drop one before it runs.
A ranked list of pharma, with what to lead with and what to bring for each, and the program matches as a dataset.
A fictional platform, matched to the top 25 pharma before a March partnering conference. Given the same question, a general AI model left Biogen out.
Pharma Partnering: immune-cell RNA platform
Its team used to take one value proposition to every pharma partner. Studio mapped every program in four newer kinds of cancer drug, the test each relies on, and who supplies it, so the team now reaches each sponsor before it chooses a diagnostic partner.
Yes. The example platform is preclinical. Sleuth sets aside any fit that depends on data you don’t have yet, and lists the proof to get first.
Yes. Add it when you shape the plan, and Sleuth maps it the same way.
Yes. Name the company, and Sleuth builds its case for and against, the objections to expect, and the proof to bring.
From each pharma’s programs, deals, and stated priorities, read franchise by franchise, with the source behind each one.
Sleuth gives the reason beside it, such as owning a competing platform, or a fit that depends on data you don’t have yet.